Video

Dr. Rivera on Screening in Lung Cancer

Author(s):

M. Patricia Rivera, MD

In Partnership With:

M. Patricia Rivera, MD, professor of medicine, UNC Chapel Hill, UNC Lineberger Comprehensive Cancer Center, discusses the recent adoption of lung cancer screening into clinical practice.

M. Patricia Rivera, MD, professor of medicine, UNC Chapel Hill, UNC Lineberger Comprehensive Cancer Center, discusses the recent adoption of lung cancer screening into clinical practice.

Screening came about following the publication of The National Lung Screening Trial. The randomized trial compared CT scan with chest X-ray in smokers over the age of 55 with a 30-year smoking history. The trial demonstrated the first reduction in mortality for patients who had been screened with CT scan.

In 2014, the United States Preventative Task Force gave this a B recommendation. In 2015, Medicare approved screening, and since then it has become more available. However, it is considerably underutilized, says Rivera. As of 2015, only 3.9% of eligible patients were being screened in the United States. This may be due, in part, to the difficulty of getting an accurate smoking history.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Related Content
Robert L. Ferris, MD, PhD, head and neck surgical oncologist, cancer center chief executive, executive director, UNC Lineberger Comprehensive Cancer Center, UNC system chief, oncology services
June 24th 2024

Robert L. Ferris, MD, PhD, Appointed Executive Director of UNC Lineberger Comprehensive Cancer Center

Yara Abdou, MD
December 7th 2023

Abdou Spotlights Factors Influencing ADC Treatment Selection in Breast Cancer

Nikita Sinha, MD
January 27th 2024

Onvansertib Induces Preclinical Anti-Tumorigenic Effects in Endometrioid Endometrial Cancer

Patrick I. Borgen, MD; Laura J. Esserman, MD, MBA; Kelly K. Hunt, MD, FACS, FSSO; Kevin Kalinsky, MD, MS; Lisa A. Carey MD, ScM, FASCO, Steven J. Chmura, MD, PhD
March 27th 2023

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

Yara Abdou, MD
September 14th 2023

Novel Treatment Regimens Populate the HR+/HER2– and HER2+ Breast Cancer Armamentariums

Ethan Basch, MD, MSc, FASCO
July 1st 2023

FOLFOX Produces Varying Toxicity Profile vs Chemoradiation in Rectal Cancer